Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 14;4(13):3141-3153.
doi: 10.1182/bloodadvances.2020001852.

First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Shu-Nan Qi  1 , Yong Yang  1 , Yu-Qin Song  2 , Ying Wang  3 , Xia He  4 , Chen Hu  5 , Li-Ling Zhang  6 , Gang Wu  6 , Bao-Lin Qu  7 , Li-Ting Qian  8 , Xiao-Rong Hou  9 , Fu-Quan Zhang  9 , Xue-Ying Qiao  10 , Hua Wang  11 , Gao-Feng Li  12 , Hui-Qiang Huang  13 , Yu-Jing Zhang  13 , Yuan Zhu  14 , Jian-Zhong Cao  15 , Jun-Xin Wu  16 , Tao Wu  17 , Su-Yu Zhu  18 , Mei Shi  19 , Li-Ming Xu  20 , Zhi-Yong Yuan  20 , Hang Su  21 , Jun Zhu  2 , Ye-Xiong Li  1
Affiliations

First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Shu-Nan Qi et al. Blood Adv. .

Erratum in

Abstract

The present study investigated the survival benefit of non-anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non-ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non-ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non-ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non-ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non-ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non-ANT-based regimens as a first-line treatment of patients with ENKTCL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.H. has received grants from the National Institutes of Health/National Cancer Institute and personal fees from Varian Medical Systems outside the submitted work. The remaining authors declare no competing financial interests. A complete list of the members of the China Lymphoma Collaborative Group appears in “Appendix.”

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS and PFS stratified by chemotherapy regimens in the entire cohort. OS (A) and PFS (B) of non–ANT-based regimens vs ANT-based regimens before PSM. OS (C) and PFS (D) of non–ANT-based regimens vs ANT-based regimens after PSM.
Figure 2.
Figure 2.
OS and PFS stratified by chemotherapy regimens in early-stage and advanced-stage diseases. OS (A) and PFS (B) of non–ANT-based regimens vs ANT-based regimens in early-stage patients before PSM. OS (C) and PFS (D) of non–ANT-based regimens vs ANT-based regimens in advanced-stage patients before PSM.
Figure 3.
Figure 3.
OS and PFS stratified by chemotherapy regimens in early-stage patients receiving CMT or chemotherapy only. OS (A) and PFS (B) of non–ANT-based regimens vs ANT-based regimens in early-stage patients receiving CMT before PSM. OS (C) and PFS (D) of non–ANT-based regimens vs ANT-based regimens in early-stage patients receiving chemotherapy only before PSM.
Figure 4.
Figure 4.
OS and PFS stratified by treatment options in early-stage patients receiving non–ANT-based or ANT-based regimens. OS (A) and PFS (B) of CMT vs CT alone in early-stage patients receiving non–ANT-based regimens before PSM. OS (C) and PFS (D) of CMT vs CT alone in early-stage patients receiving ANT-based regimens before PSM.
Figure 5.
Figure 5.
Forest plot depicting the HRs of non–ANT-based regimens vs ANT-based regimens in different risk subgroups according to the 3 risk models. KPI, Korea prognostic index; NRI, nomogram-revised risk index; PINK, prognostic index of natural killer lymphoma.
See this image and copyright information in PMC

References

    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. - PubMed
    1. Vargo JA, Patel A, Glaser SM, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States. Cancer. 2017;123(16):3176-3185. - PubMed
    1. Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29(7):1571-1577. - PubMed
    1. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181-189. - PubMed
    1. Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126(12):1424-1432, quiz 1517. - PubMed

Publication types